Cellectar Biosciences Introduces Phospholipid Ether-Drug Conjugate (PDC) Platform for Targeted Delivery of Chemotherapeutics

By: via Benzinga
Cellectar Biosciences, Inc. (NASDAQ: CLRB), an oncology-focused biotechnology company, recently introduced its Phospholipid ether-Drug ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.